A Comparative Bioavailability Trial of Steady State Semaglutide Exposure With the Current Formulation (Semaglutide) and a New Formulation (Semaglutide C) of Oral Semaglutide in Healthy Subjects
Latest Information Update: 08 Feb 2021
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 04 Feb 2021 Status changed from active, no longer recruiting to completed.
- 19 Nov 2020 Planned End Date changed from 15 Feb 2021 to 31 Jan 2021.
- 19 Nov 2020 Planned primary completion date changed from 8 Jan 2021 to 25 Dec 2020.